UK – NICE recommends Novartis’ Mayzent on the heels of SMC approval

The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Mayzent for use by NHS England, only a few days after the Scottish Medicines Consortium (SMC) approved the multiple sclerosis (MS) drug.

Mayzent (siponimod) is licensed to delay disability progression and cognitive decline in secondary progressive multiple sclerosis (SPMS) with active disease.

Following the NICE and SMC recommendations, Mayzent becomes the first oral disease-modifying therapy (DMT) approved for adult patients with SPMS in England, Wales and Scotland…